HBK Sorce Advisory LLC grew its holdings in Second Sight Medical Products Inc (NASDAQ:EYES) by 278.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 94,635 shares of the medical device company’s stock after buying an additional 69,635 shares during the quarter. HBK Sorce Advisory LLC owned 0.17% of Second Sight Medical Products worth $181,000 as of its most recent SEC filing.
Other institutional investors have also bought and sold shares of the company. Sigma Planning Corp acquired a new stake in shares of Second Sight Medical Products in the fourth quarter worth approximately $144,000. Virtu Financial LLC acquired a new stake in shares of Second Sight Medical Products in the fourth quarter worth approximately $759,000. Finally, Vanguard Group Inc. boosted its stake in shares of Second Sight Medical Products by 0.7% in the second quarter. Vanguard Group Inc. now owns 843,462 shares of the medical device company’s stock worth $1,062,000 after acquiring an additional 5,973 shares during the last quarter. Institutional investors and hedge funds own 13.48% of the company’s stock.
A number of brokerages have recently issued reports on EYES. HC Wainwright set a $5.00 price target on Second Sight Medical Products and gave the stock a “buy” rating in a research note on Monday, February 5th. Zacks Investment Research raised Second Sight Medical Products from a “sell” rating to a “hold” rating in a research note on Monday, January 8th.
Shares of Second Sight Medical Products Inc (EYES) opened at $1.91 on Tuesday. The stock has a market capitalization of $111.34, a P/E ratio of -3.60 and a beta of 3.46. Second Sight Medical Products Inc has a 12 month low of $0.90 and a 12 month high of $2.58.
Second Sight Medical Products (NASDAQ:EYES) last issued its quarterly earnings results on Wednesday, March 7th. The medical device company reported ($0.13) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.14) by $0.01. The firm had revenue of $3.10 million for the quarter, compared to analyst estimates of $1.98 million. Second Sight Medical Products had a negative return on equity of 169.01% and a negative net margin of 358.06%. The business’s revenue was up 333.6% on a year-over-year basis. During the same period in the previous year, the company posted ($0.24) earnings per share. research analysts predict that Second Sight Medical Products Inc will post -0.58 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece was published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.thelincolnianonline.com/2018/03/20/second-sight-medical-products-inc-eyes-stake-increased-by-hbk-sorce-advisory-llc.html.
Second Sight Medical Products Profile
Second Sight Medical Products, Inc is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight.
Want to see what other hedge funds are holding EYES? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Second Sight Medical Products Inc (NASDAQ:EYES).
Receive News & Ratings for Second Sight Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.